Goodnough L T, Monk T G, Sicard G, Satterfield S A, Allen B, Anderson C B, Thompson R W, Flye W, Martin K
Washington University School of Medicine, Division of Laboratory Medicine, St. Louis, MO 63110, USA.
J Vasc Surg. 1996 Aug;24(2):213-8. doi: 10.1016/s0741-5214(96)70096-4.
Although autologous blood procurement has become a standard of care in elective surgery, recent studies have questioned its cost-effectiveness. We therefore reviewed our 3-year experience with intraoperative cell salvage in patients who underwent elective abdominal aortic aneurysm repair.
A 3-year retrospective chart review of elective abdominal aortic aneurysm (infrarenal and suprarenal) repair was performed. Transthoracic repairs were excluded.
Estimated blood lost was 1748 +/- 1236 ml, or 35% of baseline blood volume (5012 +/- 689 ml). Overall, 164 (89%) received red blood cell (RBC) transfusions (3.5 +/- 2.0 U/patient). The cost per patient for cell salvage was $315 +/- $97, representing 31% of all RBC costs and 24% of total blood component costs. Mean salvage volume infused was 578 +/- 600 ml; at a mean hematocrit level of 55.7% the RBC volume infused from salvage during surgery was 313 +/- 328 ml (representing 27% of total RBC volume lost during the hospital stay). This mean RBC volume salvaged represented the equivalent of 1.6 blood bank RBC units. The mean blood bank costs saved by using cell salvage was $248, or 79% of the $315 actually spent for salvage. We found no decrease in percentage of patients undergoing transfusion until salvage volumes that were infused exceeded 750 ml, or the equivalent of two blood bank units; all of these patients who benefitted had estimated blood lost > or = 1000 ml.
We conclude that use of intraoperative cell salvage was most beneficial for patients who had estimated blood loss greater than or equal to 1000 ml and cell salvage volumes infused greater than or equal to 750 ml. Patients who are estimated to lose less than 1000 ml receive little benefit yet incur substantial costs from intraoperative cell salvage.
尽管自体血采集已成为择期手术的护理标准,但最近的研究对其成本效益提出了质疑。因此,我们回顾了3年来在接受择期腹主动脉瘤修复术患者中进行术中细胞回收的经验。
对择期腹主动脉瘤(肾下和肾上)修复进行了为期3年的回顾性图表审查。经胸修复被排除在外。
估计失血量为1748±1236毫升,占基线血容量(5012±689毫升)的35%。总体而言,164例(89%)接受了红细胞(RBC)输血(每位患者3.5±2.0单位)。细胞回收的每位患者成本为315±97美元,占所有红细胞成本的31%,占总血液成分成本的24%。平均回输回收量为578±600毫升;在平均血细胞比容水平为55.7%时,手术期间从回收中回输的红细胞体积为313±328毫升(占住院期间总红细胞丢失量的27%)。回收的平均红细胞体积相当于1.6个血库红细胞单位。使用细胞回收节省的平均血库成本为248美元,占实际用于回收的315美元的79%。我们发现,直到回输的回收量超过750毫升或相当于两个血库单位,接受输血的患者百分比才会下降;所有这些受益患者的估计失血量均≥1000毫升。
我们得出结论,术中细胞回收对估计失血量大于或等于1000毫升且回输的细胞回收量大于或等于750毫升的患者最为有益。估计失血量少于1000毫升的患者获益甚微,但术中细胞回收会产生大量成本。